SSB 5924
In CommitteeSenate
Pharmacist prescriptive auth
Expanding prescriptive authority for pharmacists.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill expands pharmacists’ authority to independently diagnose and prescribe medications in Washington State, removing the requirement for physician-led collaborative agreements. It reflects a legislative finding that pharmacists are highly trained professionals whose current scope of practice is outdated and underutilized, especially in areas with limited provider access.
- Authorizes pharmacists to independently diagnose and prescribe medications based on their education, training, and experience—without requiring a collaborative drug therapy agreement with a physician.
- Removes the requirement for pharmacists to file and maintain collaborative drug therapy agreements, eliminating an administrative burden the legislature found does not improve patient safety or outcomes.
- Confirms that pharmacists have long held prescriptive authority under such agreements since 1979, and that no patient harm has been documented in state records.
- Amends definitions in Chapter 18.64 RCW to clarify the scope of pharmacy practice, including the ability to 'initiate or modify drug therapy' and 'diagnose and prescribe' based on professional judgment.
- Revises RCW 69.41.030 to explicitly include pharmacists as authorized prescribers, removing outdated language limiting their authority to 'drug therapy guidelines or protocols' approved by a physician.
Who is affected
- Pharmacists — Pharmacists gain expanded authority to diagnose and prescribe medications independently, without requiring a collaborative agreement with a physician, allowing them to manage patient care more fully within their scope of training.
- Patients, especially in rural or underserved communities — Patients in rural, underserved, or medically underserved areas gain improved access to care, as pharmacists can now provide more direct clinical services—including chronic disease management—without needing physician oversight.
- Health care providers and systems — Health care systems and clinics may benefit from pharmacists taking on more direct patient management roles, potentially reducing provider burden and improving care coordination for conditions like diabetes, heart disease, and behavioral health.
- Pharmacy regulatory agencies — The Pharmacy Quality Assurance Commission will transition from overseeing collaborative drug therapy agreements to regulating pharmacists' independent practice under updated standards and guidelines.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (4)
Patients in rural and underserved areas—where physician shortages are acute—will gain significantly improved access to medication management for chronic conditions (e.g., diabetes, hypertension, behavioral health) directly from pharmacists, reducing travel time, wait times, and out-of-pocket costs for care.
HealthcarePeopleRef: Sec. 1(2) and Sec. 2(32)Pharmacists and community pharmacies will experience reduced administrative burden and overhead costs associated with maintaining and filing collaborative drug therapy agreements, enabling them to redirect resources toward direct patient care and potentially expand services like immunizations, point-of-care testing, and chronic disease management.
Business & EmploymentPeopleRef: Sec. 1(4) and Sec. 2 (elimination of collaborative agreement filing)By removing the requirement for physician approval of drug therapy protocols, the bill enables pharmacists to respond more quickly to evolving patient needs—especially in time-sensitive areas like behavioral health and addiction treatment—potentially improving outcomes for conditions where timely intervention is critical.
HealthcarePeopleRef: Sec. 1(3) and Sec. 2(32)The expansion aligns Washington with national trends (e.g., California, Oregon, Colorado) where pharmacist prescriptive authority has been implemented without documented increases in adverse events, suggesting potential for improved continuity of care and reduced strain on primary care providers.
HealthcarePeopleRef: Sec. 1(1) and Sec. 2(32)
Potential Concerns (3)
Expanding pharmacists’ authority to independently diagnose and prescribe removes the physician oversight layer that has historically provided an additional safety check—particularly for complex or high-risk conditions—potentially increasing risk of misdiagnosis or inappropriate medication selection, especially in cases where pharmacists lack full clinical context or access to comprehensive patient records.
Public SafetyPeopleRef: Sec. 2(32) (new language in 'Practice of pharmacy')While the bill claims no patient harm has occurred under collaborative agreements, the absence of documented harm does not prove absence of risk; removing structured oversight mechanisms may reduce accountability and create gaps in care coordination, especially for patients with complex multimorbidity or polypharmacy.
HealthcarePeopleRef: Sec. 1(4) and Sec. 2 (elimination of collaborative agreement filing requirement)The bill relies heavily on pharmacists’ professional judgment without requiring standardized competency assessments or mandatory continuing education in diagnosis—raising concerns about variability in diagnostic accuracy and consistency across pharmacists, particularly in rural or under-resourced settings where oversight is already limited.
Public SafetyLean peopleRef: Sec. 2(32) (expansion of 'Practice of pharmacy' to include 'diagnosing and prescribing...based on education, training, and experience')
Who Is Most Affected
Pharmacists gain independent prescriptive authority, increasing autonomy, job satisfaction, and potential earnings—especially those in clinical or community settings offering chronic care services.
Rural, low-income, and uninsured patients benefit most from improved access to medication management without needing to schedule separate appointments with physicians; however, those with complex or unstable conditions may face higher risk if pharmacists lack full clinical context.
Primary care providers may experience reduced administrative and clinical burden as pharmacists take over routine medication management for stable chronic conditions, but clinics may face challenges integrating pharmacists into care teams without formal referral or communication protocols.
Large pharmacy chains and health systems that employ pharmacists in clinical roles stand to benefit from improved care coordination and reduced provider burnout, but may face initial costs in updating workflows, training, and EHR integration.
Pharmacy regulators (PQAC) will shift from overseeing collaborative agreements to developing new competency standards and monitoring independent practice—requiring new regulatory capacity but potentially streamlining oversight.